Literature DB >> 11673036

Vancomycin levels in human aqueous humour after intravenous and subconjunctival administration.

M Souli1, G Kopsinis, E Kavouklis, L Gabriel, H Giamarellou.   

Abstract

The purpose of the present study was to evaluate the level of vancomycin in human aqueous humour after intravenous (i.v.) and subconjunctival administration. One hundred patients scheduled to undergo cataract extraction participated in the study. Fifty-three of them received 20 mg vancomycin subconjunctivally and 47 received two doses of vancomycin i.v. (1 g b.i.d.). Specimens of aqueous humour from the first group were collected 1, 2, 2.5, 3, 3.5, 5, 6, 7, and 8 h after the subconjunctival injection. In the second group, specimens of blood and aqueous humour were collected 1, 2, 4, 6, 8, 10, and 12 h after the end of infusion of the second dose of the antibiotic. The levels of vancomycin were determined by fluorescent polarization immunoassay. In the first group peak levels of 24.82+/-3.55 microg/ml were achieved in aqueous humour at 5 h, whereas in the second group peak levels of 1.42+/-0.47 microg/ml were detected at 6 h. The latter levels, although higher than the MICs of most of the Gram-positive pathogens causing eye infections, are inadequate for the treatment of infections in vivo. These results support the need for subconjunctival instead of i.v. administration of vancomycin in order to achieve therapeutic levels of the drug in human aqueous humour or for prophylactic use whenever indicated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673036     DOI: 10.1016/s0924-8579(01)00375-2

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

Review 1.  Prophylaxis of postoperative endophthalmitis following cataract surgery: current status and future directions.

Authors:  Robert E Fintelmann; Ayman Naseri
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

2.  Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging.

Authors:  S Kevin Li; Sarah A Molokhia; Eun-Kee Jeong
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

3.  Modeling of corneal and retinal pharmacokinetics after periocular drug administration.

Authors:  Aniruddha C Amrite; Henry F Edelhauser; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

4.  Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene.

Authors:  Y De Kozak; B Thillaye-Goldenberg; M-C Naud; A Vianna Da Costa; C Auriault; C Verwaerde
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

5.  Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin.

Authors:  M Cahane; G J Ben Simon; I S Barequet; A Grinbaum; L Diamanstein-Weiss; O Goller; E Rubinstein; I Avni
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

6.  Controlled Release of Vancomycin From a Thermoresponsive Hydrogel System for the Prophylactic Treatment of Postoperative Acute Endophthalmitis.

Authors:  Emily Dosmar; Wenqiang Liu; Geeya Patel; Alison Rogozinski; William F Mieler; Jennifer J Kang-Mieler
Journal:  Transl Vis Sci Technol       Date:  2019-06-27       Impact factor: 3.283

7.  Brachybacterium paraconglomeratum Endophthalmitis Postcataract Operation.

Authors:  Kazuhiro Murata; Kenji Ozawa; Hideaki Kawakami; Kiyofumi Mochizuki; Kiyofumi Ohkusu
Journal:  Case Rep Ophthalmol Med       Date:  2020-03-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.